USPTO serial 90602703
HEALTH. ILLUMINATED.
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 14, 2023
- Examiner
- DE JONGE, KATHLEEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HEALTH. ILLUMINATED.?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Salt Lake City, UT, US
Salt Lake City, UT, US
Salt Lake City, UT, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joyce M. Ferraro
Joyce M. Ferraro Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th FloorNew York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical test kits comprising chemical reagents and chemical preparations for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; medical diagnostic reagents, assays, chemical preparations, and diagnostic test kits consisting primarily of reagents for medical diagnostic purposes, namely, testing of fluids; chemical reagents for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic test kits comprised of chemical reagents and chemical preparations for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic kits consisting primarily of reagents for body fluid analysis and nucleic acid analysis and for detecting genetic conditions, disorders, and diseases for medical use | ACTIVE | — |
| 010 | Medical test kits comprising specimen collection tubes and containers for collecting patient specimens, printed test forms, printed mailing materials, and printed user information inserts used in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; sample preparation device for medical diagnostic uses; medical apparatus and instruments for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of tissue-based diagnostic testing, cytology and cell-based testing; blood, urine, and saliva medical specimen collection kits consisting of test tubes and self-mailer, used for health and genetic analysis and diagnostics | ACTIVE | — |
| 042 | Clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human genetics, for scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs, and the environment; providing temporary use of non-downloadable computer software for customizing, selecting, and ordering health and genetic analysis and diagnostic kits and assays and for accessing, viewing, and storing health and genetic information via electronic, optical, and wireless communication networks; scientific research analysis and consulting services which use bioinformatics; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies and development of new medical and scientific products and validation thereof | ACTIVE | Jun 23, 2021 |
| 044 | Genetic testing services for diagnostic or treatment purposes; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of genetics, namely, the identification of genes that predispose individuals to common diseases and health disorders for diagnostic or treatment purposes; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing, monitoring, and reporting services; internet-based health care information services; providing an internet website for medical professionals featuring medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical information, namely, providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through personalized pharmacogenetic testing, proteomics and other biological testing, individual behaviors including medication compliance, exercise diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis and medical and pharmaceutical consultation services related thereto, namely, discussion and interpretation with clients of medical test results and medical analysis related thereto; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorption, distribution, metabolism, and excretion and each medication's receptor activity, mechanism of action, and pathways of response and then measures the impact of genomic changes across these pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patients, personalize medication selection, and treatment options and choices for patients, identify potentially harmful drug interactions, and calculate drug dosage adjustments for patients; and medical information services, namely, preparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objective, evidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications | ACTIVE | Jun 23, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Myriad Genetics, Inc.
- Other trademarks owned by Myriad Genetics, Inc.
- Other trademarks owned by Myriad Genetics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named HEALTH. ILLUMINATED.
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 2, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jul 9, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 9, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 9, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 9, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 9, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 26, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 14, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 14, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 7, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 6, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 6, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 5, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 5, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 4, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 14, 2022 | IUAF | USE AMENDMENT FILED | — |
| Dec 14, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 14, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 14, 2022 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 27, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 25, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 25, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 25, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 17, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 17, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 17, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 17, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 17, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 27, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 27, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jan 27, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 27, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 25, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 30, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 30, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 10, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 25, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 25, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 25, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 25, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 25, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 8, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 6, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 30, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 29, 2021 | NWAP | NEW APPLICATION ENTERED | — |